Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894572 | 0.91 | — | — | |
| SCHEMBL11968955 | 0.87 | HTR6 (0.45) | HTR6 | |
| SCHEMBL3534078 | 0.85 | HTR6 (0.44) | HTR6 | |
| SCHEMBL2265420 | 0.74 | HTR2C (0.33) | HTR2CHTR2AKMT2AMEN1ALDH1A1 | |
| SCHEMBL352142 | 0.72 | HTR2C (0.33) | HTR2CHTR2AHTR6KMT2AMEN1 | |
| SCHEMBL27729342 | 0.71 | HTR2C (0.33) | HTR2CHTR2AKMT2AMEN1ALDH1A1 | |
| SCHEMBL5969664 | 0.71 | HTR2C (0.32) | HTR2CHTR2AHTR6KMT2AMEN1 | |
| SCHEMBL16716848 | 0.69 | MEN1 (0.33) | HTR2CHTR2AKMT2AMEN1ALDH1A1 | |
| SCHEMBL336575 | 0.66 | HTR6 (0.50) | HTR2CHTR2AHTR6KMT2AMEN1 | |
| SCHEMBL1400974 | 0.66 | HTR6 (0.50) | HTR2CHTR2AHTR6KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1938291-B | Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA NV | 2011-11-16 | — | — | CN | disclosed |
| EP-1581518-B1 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-PYRROLIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| US-7795261-B2 | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7572786-B2 | Irritable bowel syndrome; tachykinin mediated condition such as schizophrenia, emesis, anxiety, depression, irritable bowel syndrome, circadian rhythm disturbances, pain, neurogenic inflammation, asthma, micturition disorder or nociception | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-08-11 | — | — | US | disclosed |
| CN-100482229-C | Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-29 | — | — | CN | disclosed |
| US-7514424-B2 | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-07 | — | — | US | disclosed |
| EP-1551804-B1 | SUBSTITUTED 1,4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-12-24 | — | — | EP | disclosed |
| US-7435736-B2 | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-10-14 | — | — | US | disclosed |
| US-7410970-B2 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-12 | — | — | US | disclosed |
| EP-1578744-B1 | SUBSTITUTED 4-(4-PIPERIDIN-4-YL-PIPERAZIN-1-YL)-AZEPANE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2008-07-09 | — | — | EP | disclosed |
| EP-1581517-B1 | SUBSTITUTED 1-PIPERIDIN-4-YL-4-AZETIDIN-3-YL-PIPERAZINE DERIVATIVES AND THEIR USE AS NEUROKININ ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-21 | — | — | EP | disclosed |
| US-20060252747-A1 | Substitituted 1-piperidin-3-yl-piperidin 4-yl-piperazine derivatives and their use as neurokinin auantagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-11-09 | — | — | US | disclosed |
| US-20060167008-A1 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | ELANCO ANIMAL HEALTH IRELAND LIMITED (IE) | 2006-07-27 | — | — | US | disclosed |
| US-20060128721-A1 | Novel formulations of opioid-based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives | JANSSENS FRANS E | 2006-06-15 | — | — | US | disclosed |
| US-20060074069-A1 | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-04-06 | — | — | US | disclosed |
| EP-1635811-A2 | SUBSTITUTED 1, 4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVE COMBINED WITH AN OPIOID ANALGESIC AND THEIR USE FOR THE TREATMENT OF PAIN AND SIDE-EFFECTS ASSOCIATED WITH OPIOID-BASED TREATMENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-22 | — | — | EP | disclosed |
| US-20060058285-A1 | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-03-16 | — | — | US | disclosed |
| US-20060040950-A1 | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
| CN-1728999-A | Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2006-02-01 | — | — | CN | disclosed |
| WO-2004110415-A2 | SUBSTITUTED 1, 4-DI-PIPERIDIN-4-YL-PIPERAZINE DERIVATIVE COMBINED WITH AN OPIOID ANALGESIC AND THEIR USE FOR THE TREATMENT OF PAIN AND SIDE-EFFECTS ASSOCIATED WITH OPIOID-BASED TREATMENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167008-A1 | Substituted 1,4,-di-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | NPSR1, VIP, TACR1 | HTR2C 36/4885HTR2A 23/4885HTR6 288/4885 |
| US-20060252747-A1 | Substitituted 1-piperidin-3-yl-piperidin 4-yl-piperazine derivatives and their use as neurokinin auantagonists | NPSR1, VIP, VIPR2 | HTR2C 79/4885HTR2A 52/4885HTR6 539/4885 |
| US-20060058285-A1 | Substituted 4-(4-piperidin-4-yl-piperazin-1-yl)-azepane derivatives and their use as neurokinin antagonists | NPSR1, TACR1, NPY1R | HTR2C 24/4885HTR2A 21/4885HTR6 251/4885 |
| US-20060074069-A1 | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | NPSR1, TACR1, VIP | HTR2C 122/4885HTR2A 99/4885HTR6 469/4885 |
| US-20060040950-A1 | Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | NPSR1, TACR1, VIP | HTR2C 48/4885HTR2A 44/4885HTR6 383/4885 |
| US-20060128721-A1 | Novel formulations of opioid-based treatments of pain comprising substituted 1,4-di-piperidin-4-yl-piperazine derivatives | OPRK1, OPRL1, OPRM1 | HTR2C 266/4885HTR2A 338/4885HTR6 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.